- Home
- ORMP vs IMNM Comparison
ORMP vs IMNM Comparison
Compare ORMP & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ORMP
- IMNM
- Stock Information
- Founded
- ORMP 2002
- IMNM 2006
- Country
- ORMP United States
- IMNM United States
- Employees
- ORMP N/A
- IMNM N/A
- Industry
- ORMP Biotechnology: Pharmaceutical Preparations
- IMNM Medicinal Chemicals and Botanical Products
- Sector
- ORMP Health Care
- IMNM Health Care
- Exchange
- ORMP Nasdaq
- IMNM Nasdaq
- Market Cap
- ORMP N/A
- IMNM 748.3M
- IPO Year
- ORMP N/A
- IMNM 2020
- Fundamental
- Price
- ORMP $2.20
- IMNM $8.84
- Analyst Decision
- ORMP Hold
- IMNM Strong Buy
- Analyst Count
- ORMP 1
- IMNM 5
- Target Price
- ORMP N/A
- IMNM $26.40
- AVG Volume (30 Days)
- ORMP 77.2K
- IMNM 1.0M
- Earning Date
- ORMP 08-15-2025
- IMNM 08-11-2025
- Dividend Yield
- ORMP N/A
- IMNM N/A
- EPS Growth
- ORMP N/A
- IMNM N/A
- EPS
- ORMP N/A
- IMNM N/A
- Revenue
- ORMP $2,000,000.00
- IMNM $10,938,000.00
- Revenue This Year
- ORMP N/A
- IMNM N/A
- Revenue Next Year
- ORMP N/A
- IMNM $310.65
- P/E Ratio
- ORMP N/A
- IMNM N/A
- Revenue Growth
- ORMP 196.74
- IMNM N/A
- 52 Week Low
- ORMP $1.82
- IMNM $5.15
- 52 Week High
- ORMP $3.09
- IMNM $16.81
- Technical
- Relative Strength Index (RSI)
- ORMP 49.72
- IMNM 50.27
- Support Level
- ORMP $2.10
- IMNM $8.35
- Resistance Level
- ORMP $2.25
- IMNM $9.34
- Average True Range (ATR)
- ORMP 0.09
- IMNM 0.53
- MACD
- ORMP 0.00
- IMNM -0.07
- Stochastic Oscillator
- ORMP 63.16
- IMNM 33.97
About IMNM Immunome Inc.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.